Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors

G. Caocci, O. Mulas, M. Annunziata, L. Luciano, E. Abruzzese, M. Bonifacio, E.M. Orlandi, F. Albano, S. Galimberti, A. Iurlo, P. Pregno, N. Sgherza, B. Martino, G. Binotto, F. Castagnetti, A. Gozzini, M. Bocchia, C. Fozza, F. Stagno, M.P. SimulaF. De Gregorio, M.M. Trawinska, L. Scaffidi, C. Elena, I. Attolico, C. Baratè, D. Cattaneo, F. Pirillo, G. Gugliotta, A. Sicuranza, M. Molica, G. La Nasa, R. Foà, M. Breccia

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)163-166
Number of pages4
JournalInternational Journal of Cardiology
Volume301
DOIs
Publication statusPublished - 2020

Keywords

  • a
  • Cardiovascular toxicity
  • Chronic myeloid leuk
  • emia
  • Ischemic heart disease
  • TKI
  • bosutinib
  • dasatinib
  • nilotinib
  • ponatinib
  • adult
  • age distribution
  • aged
  • Article
  • body mass
  • cancer growth
  • cardiovascular disease
  • cardiovascular mortality
  • cardiovascular risk
  • chronic myeloid leukemia
  • cohort analysis
  • comorbidity
  • diabetes mellitus
  • epidemiological data
  • female
  • human
  • incidence
  • ischemic heart disease
  • Italian (citizen)
  • kidney failure
  • major clinical study
  • male
  • medical history
  • mortality rate
  • preventive medicine
  • primary health care
  • priority journal
  • retrospective study
  • risk factor
  • secondary health care
  • sex difference
  • smoking habit
  • standardized mortality ratio
  • survival rate
  • systolic blood pressure
  • total cholesterol level
  • very elderly

Cite this

Caocci, G., Mulas, O., Annunziata, M., Luciano, L., Abruzzese, E., Bonifacio, M., Orlandi, E. M., Albano, F., Galimberti, S., Iurlo, A., Pregno, P., Sgherza, N., Martino, B., Binotto, G., Castagnetti, F., Gozzini, A., Bocchia, M., Fozza, C., Stagno, F., ... Breccia, M. (2020). Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. International Journal of Cardiology, 301, 163-166. https://doi.org/10.1016/j.ijcard.2019.10.036